Technology evaluation: ipilimumab, Medarex/Bristol-Myers Squibb.
Published
Journal Article
Medarex and Bristol-Myers Squibb are developing ipilimumab, an immunostimulatory human antibody against cytotoxic T-lymphocyte antigen-4, for the potential combination or monotherapy treatment of melanoma, prostate, breast, renal and other cancers, as well as HIV infection.
Full Text
Duke Authors
Cited Authors
- Morse, MA
Published Date
- December 2005
Published In
Volume / Issue
- 7 / 6
Start / End Page
- 588 - 597
PubMed ID
- 16370382
Pubmed Central ID
- 16370382
International Standard Serial Number (ISSN)
- 1464-8431
Language
- eng
Conference Location
- England